Viking Therapeutics (VKTX) EBT (2014 - 2026)
Viking Therapeutics (VKTX) posted EBT of -$263.9 million for Q2 2026, up 0.93% sequentially from -$266.4 million in Q1 2026, and down 74.59% YoY from -$1.0 billion in Q2 2025.
Viking Therapeutics (VKTX) EBT (2014 - 2026) Analysis & Trends
Viking Therapeutics has reported EBT for 13 years, with the latest figure at -$263.9 million in Q2 2026.
- Quarterly EBT fell 74.59% year-over-year to -$263.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$982.0 million (down 27.03% YoY) and the FY2025 annual result came in at -$506.2 million, down 60.61% from the prior year.
- EBT rose to -$263.9 million in Q2 2026 per VKTX's latest filing, from -$266.4 million in the prior quarter.
- Over five years, EBT peaked at -$17.8 million in Q3 2022 and troughed at -$60.3 billion in Q1 2023.
- A 5-year average of -$7.6 billion and a median of -$235.1 million in 2024 frame the typical range for EBT.
- The sharpest annual moves came in 2023 and 2024: EBT plunged 318707.31% in 2023, then soared 99.48% in 2024.
- Over 5 years, EBT stood at -$40.3 million in 2022, then tumbled by 126.06% to -$91.1 million in 2023, then tumbled by 133.47% to -$212.6 million in 2024, then sank by 31.12% to -$278.7 million in 2025, then climbed by 5.33% to -$263.9 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$263.9 million, -$266.4 million, and -$278.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - | -263.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -263.90 Mn |
| Mar 31, 2026 | -266.38 Mn |
| Dec 31, 2025 | -278.75 Mn |
| Sep 30, 2025 | -173.02 Mn |
| Jun 30, 2025 | -151.16 Mn |
| Mar 31, 2025 | -121.30 Mn |
| Dec 31, 2024 | -212.59 Mn |
| Sep 30, 2024 | -288.03 Mn |
| Jun 30, 2024 | -257.58 Mn |
| Mar 31, 2024 | -436.20 Mn |
| Dec 31, 2023 | -91.06 Mn |
| Sep 30, 2023 | -23.36 Bn |
| Jun 30, 2023 | -49.62 Bn |
| Mar 31, 2023 | -60.35 Bn |
| Dec 31, 2022 | -40.28 Mn |
| Sep 30, 2022 | -17.85 Mn |
| Jun 30, 2022 | -19.45 Mn |
| Mar 31, 2022 | -18.93 Mn |
| Dec 31, 2021 | -15.77 Mn |
| Sep 30, 2021 | -18.95 Mn |